{"format":{"id":"vaccine","name":"Cancer vaccines","blurb":"An antigen to teach the immune system and a platform to deliver the lesson: mRNA in lipid nanoparticles, peptides, DNA plasmids, viral vectors, dendritic cells, whole cells or virus-like particles.","axes":["antigen","platform"],"axisLabels":["Antigen","Platform"],"components":[{"key":"antigen","label":"Antigen"},{"key":"platform","label":"Platform"},{"key":"target","label":"Target"}]},"counts":{"approved":2,"development":11,"stopped":2,"unclear":0,"untried":94,"drugs":21,"partial":2,"unresolved":4},"coverage":{"total":25,"full":19,"partial":2,"unresolved":4,"pct":84},"rows":[{"key":"antigen","id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/"},{"key":"antigen","id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/"},{"key":"antigen","id":"alpha-gal","name":"Alpha-gal (xenoantigen)"},{"key":"antigen","id":"tumour-lysate","name":"Autologous tumour lysate"},{"key":"antigen","id":"brachyury","name":"Brachyury (TBXT)"},{"key":"antigen","id":"her2","name":"HER2","href":"/targets/her2/"},{"key":"antigen","id":"her2+ceacam5+tp53","name":"HER2 x CEACAM5 x TP53","href":"/targets/her2/"},{"key":"antigen","id":"kras","name":"KRAS","href":"/targets/kras/"},{"key":"antigen","id":"pdl1+ido1","name":"PD-L1 x IDO1","href":"/targets/pdl1/"},{"key":"antigen","id":"pap","name":"Prostatic acid phosphatase (ACP3, PAP)","href":"/targets/pap/"},{"key":"antigen","id":"psma","name":"PSMA","href":"/targets/psma/"},{"key":"antigen","id":"glycan","name":"Tumour glycan (Globo H)"}],"cols":[{"key":"platform","id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/"},{"key":"platform","id":"vlp","name":"Virus-like particle","href":"/technologies/hpv-vaccine/"},{"key":"platform","id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/"},{"key":"platform","id":"mrna","name":"mRNA","href":"/technologies/neoantigen-mrna-vaccine/"},{"key":"platform","id":"dna-plasmid","name":"DNA plasmid","href":"/technologies/shared-antigen-vaccine/"},{"key":"platform","id":"glycoconjugate","name":"Glycoconjugate","href":"/technologies/shared-antigen-vaccine/"},{"key":"platform","id":"yeast","name":"Recombinant yeast","href":"/technologies/shared-antigen-vaccine/"},{"key":"platform","id":"viral-vector","name":"Viral vector","href":"/technologies/shared-antigen-vaccine/"},{"key":"platform","id":"whole-cell","name":"Whole cell","href":"/technologies/shared-antigen-vaccine/"},{"key":"platform","id":"not-recorded","name":"Platform not recorded"}],"cells":[{"a":{"key":"antigen","id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/"},"b":{"key":"platform","id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/"},"state":"development","drugs":[{"id":"neovax","name":"NeoVax","route":"/drugs/neovax/","state":"development","status":"phase-1"},{"id":"rindopepimut","name":"Rindopepimut","route":"/drugs/rindopepimut/","state":"stopped","status":"negative"}],"counts":{"approved":0,"development":1,"stopped":1,"unclear":0},"parts":{"target":[{"key":"target","id":"egfr","name":"EGFR","href":"/targets/egfr/"}]},"evidence":[{"record":"neovax","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 1","href":"/drugs/neovax/"},{"record":"rindopepimut","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/rindopepimut/","quote":"Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape."},{"record":"act-iv","field":"result","kind":"trial","state":"stopped","label":"ACT IV: phase 3, negative","href":"/trials/act-iv/","quote":"OS 20.1 vs 20.0 months; no benefit."}],"reasons":[{"drugId":"rindopepimut","drugName":"Rindopepimut","drugRoute":"/drugs/rindopepimut/","drugState":"stopped","record":"rindopepimut","kind":"drug","label":"Drug record status: negative","href":"/drugs/rindopepimut/","quote":"Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape."},{"drugId":"rindopepimut","drugName":"Rindopepimut","drugRoute":"/drugs/rindopepimut/","drugState":"stopped","record":"act-iv","kind":"trial","label":"ACT IV: phase 3, negative","href":"/trials/act-iv/","quote":"OS 20.1 vs 20.0 months; no benefit."}]},{"a":{"key":"antigen","id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/"},"b":{"key":"platform","id":"mrna","name":"mRNA","href":"/technologies/neoantigen-mrna-vaccine/"},"state":"development","drugs":[{"id":"autogene-cevumeran","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","state":"development","status":"phase-2"},{"id":"intismeran-autogene","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":2,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"autogene-cevumeran","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/autogene-cevumeran/"},{"record":"nct05968326","field":"status","kind":"trial","state":"development","label":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC: phase 2, active","href":"/trials/nct05968326/"},{"record":"registry:autogene-cevumeran","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/autogene-cevumeran/#registry"},{"record":"intismeran-autogene","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/intismeran-autogene/"},{"record":"nct06833073","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011): phase 2, recruiting","href":"/trials/nct06833073/"},{"record":"nct06961006","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012): phase 2, recruiting","href":"/trials/nct06961006/"},{"record":"nct06305767","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005): phase 1/2, active","href":"/trials/nct06305767/"},{"record":"nct07513376","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I : phase 3, recruiting","href":"/trials/nct07513376/"},{"record":"nct06307431","field":"status","kind":"trial","state":"development","label":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).: phase 2, active","href":"/trials/nct06307431/"},{"record":"nct06077760","field":"status","kind":"trial","state":"development","label":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (: phase 3, active","href":"/trials/nct06077760/"},{"record":"nct07221474","field":"status","kind":"trial","state":"development","label":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013): phase 2, recruiting","href":"/trials/nct07221474/"},{"record":"nct06623422","field":"status","kind":"trial","state":"development","label":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009): phase 3, recruiting","href":"/trials/nct06623422/"},{"record":"nct03897881","field":"status","kind":"trial","state":"development","label":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN: phase 2, active","href":"/trials/nct03897881/"},{"record":"registry:intismeran-autogene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/intismeran-autogene/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/"},"b":{"key":"platform","id":"not-recorded","name":"Platform not recorded"},"state":"development","drugs":[{"id":"grt-c901","name":"GRT-C901","route":"/drugs/grt-c901/","state":"development","status":"phase-3"},{"id":"grt-r902","name":"GRT-R902","route":"/drugs/grt-r902/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":2,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"grt-c901","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/grt-c901/"},{"record":"nct05141721","field":"status","kind":"trial","state":"development","label":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer: phase 2/3, active","href":"/trials/nct05141721/"},{"record":"registry:grt-c901","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/grt-c901/#registry"},{"record":"grt-r902","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/grt-r902/"},{"record":"nct05141721","field":"status","kind":"trial","state":"development","label":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer: phase 2/3, active","href":"/trials/nct05141721/"},{"record":"registry:grt-r902","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/grt-r902/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/"},"b":{"key":"platform","id":"vlp","name":"Virus-like particle","href":"/technologies/hpv-vaccine/"},"state":"approved","drugs":[{"id":"cervavac","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","state":"approved","status":"approved"},{"id":"hpv-bivalent-vaccine","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","state":"approved","status":"approved"},{"id":"hpv-quadrivalent-vaccine","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","state":"approved","status":"approved"},{"id":"gardasil-9","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","state":"approved","status":"approved"}],"counts":{"approved":4,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"cervavac","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cervavac/"},{"record":"cervavac","field":"approvals[0]","kind":"approval","state":"approved","label":"IN 2022: Prevention of HPV 6/11/16/18-related cancers and genital warts, ages 9-26","href":"/drugs/cervavac/"},{"record":"cervavac","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved 2022","href":"https://www.seruminstitute.com/product_ind_cervavac.php"},{"record":"registry:cervavac","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/cervavac/#registry"},{"record":"hpv-bivalent-vaccine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/hpv-bivalent-vaccine/"},{"record":"hpv-bivalent-vaccine","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2007: Prevention of premalignant cervical lesions and cervical cancer caused by HPV 16 and 18 from age 9 (Cervarix); anal lesions added later","href":"/drugs/hpv-bivalent-vaccine/"},{"record":"hpv-bivalent-vaccine","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2009: Prevention of cervical cancer and precursor lesions caused by HPV 16 and 18 in females 10 to 25 (discontinued in the US 2016)","href":"/drugs/hpv-bivalent-vaccine/"},{"record":"hpv-bivalent-vaccine","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2007","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix"},{"record":"registry:hpv-bivalent-vaccine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/hpv-bivalent-vaccine/#registry"},{"record":"hpv-quadrivalent-vaccine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/hpv-quadrivalent-vaccine/"},{"record":"hpv-quadrivalent-vaccine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: Prevention of cervical, vulvar and vaginal cancers and precancers and genital warts caused by HPV 6, 11, 16 and 18 in females 9 to 26 (males 2009; anal cancer 2010); superseded by Gardasil 9","href":"/drugs/hpv-quadrivalent-vaccine/"},{"record":"hpv-quadrivalent-vaccine","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2006: Prevention of premalignant genital lesions, cervical cancer and genital warts from age 9 (Gardasil); anal lesions and cancer added later","href":"/drugs/hpv-quadrivalent-vaccine/"},{"record":"hpv-quadrivalent-vaccine","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil"},{"record":"nct06465914","field":"status","kind":"trial","state":"development","label":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males: phase 3, active","href":"/trials/nct06465914/"},{"record":"nct04422366","field":"status","kind":"trial","state":"development","label":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females: phase 3, recruiting","href":"/trials/nct04422366/"},{"record":"registry:hpv-quadrivalent-vaccine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/hpv-quadrivalent-vaccine/#registry"},{"record":"gardasil-9","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gardasil-9/"},{"record":"gardasil-9","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Prevention of HPV-related cancers and precancers, ages 9-26; extended to 45 in 2018","href":"/drugs/gardasil-9/"},{"record":"gardasil-9","field":"approvals[1]","kind":"approval","state":"approved","label":"WHO 2022: Single-dose schedule recommended for girls 9-20","href":"/drugs/gardasil-9/"},{"record":"gardasil-9","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"gardasil-9","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil-9"},{"record":"gardasil-9","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Gardasil%209"},{"record":"gardasil-9","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"gardasil-9","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"gardasil-9","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Gardasil%209"},{"record":"registry:gardasil-9","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/gardasil-9/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/"},"b":{"key":"platform","id":"viral-vector","name":"Viral vector","href":"/technologies/shared-antigen-vaccine/"},"state":"development","drugs":[{"id":"hb-200","name":"HB-200","route":"/drugs/hb-200/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"hb-200","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/hb-200/"}],"reasons":[]},{"a":{"key":"antigen","id":"alpha-gal","name":"Alpha-gal (xenoantigen)"},"b":{"key":"platform","id":"whole-cell","name":"Whole cell","href":"/technologies/shared-antigen-vaccine/"},"state":"stopped","drugs":[{"id":"algenpantucel-l","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/","state":"stopped","status":"negative"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"algenpantucel-l","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/algenpantucel-l/","quote":"Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit."},{"record":"impress-trial","field":"result","kind":"trial","state":"stopped","label":"IMPRESS (algenpantucel-L): phase 3, negative","href":"/trials/impress-trial/","quote":"No overall survival benefit."},{"record":"registry:algenpantucel-l","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 3 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/algenpantucel-l/#registry"}],"reasons":[{"drugId":"algenpantucel-l","drugName":"Algenpantucel-L","drugRoute":"/drugs/algenpantucel-l/","drugState":"stopped","record":"algenpantucel-l","kind":"drug","label":"Drug record status: negative","href":"/drugs/algenpantucel-l/","quote":"Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit."},{"drugId":"algenpantucel-l","drugName":"Algenpantucel-L","drugRoute":"/drugs/algenpantucel-l/","drugState":"stopped","record":"impress-trial","kind":"trial","label":"IMPRESS (algenpantucel-L): phase 3, negative","href":"/trials/impress-trial/","quote":"No overall survival benefit."}]},{"a":{"key":"antigen","id":"tumour-lysate","name":"Autologous tumour lysate"},"b":{"key":"platform","id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/"},"state":"development","drugs":[{"id":"dcvax-l","name":"DCVax-L","route":"/drugs/dcvax-l/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"dcvax-l","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/dcvax-l/"},{"record":"registry:dcvax-l","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/dcvax-l/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"brachyury","name":"Brachyury (TBXT)"},"b":{"key":"platform","id":"yeast","name":"Recombinant yeast","href":"/technologies/shared-antigen-vaccine/"},"state":"stopped","drugs":[{"id":"gi-6301","name":"GI-6301","route":"/drugs/gi-6301/","state":"stopped","status":"negative"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"gi-6301","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/gi-6301/","quote":"GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses."},{"record":"registry:gi-6301","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 17 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/gi-6301/#registry"}],"reasons":[{"drugId":"gi-6301","drugName":"GI-6301","drugRoute":"/drugs/gi-6301/","drugState":"stopped","record":"gi-6301","kind":"drug","label":"Drug record status: negative","href":"/drugs/gi-6301/","quote":"GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses."}]},{"a":{"key":"antigen","id":"her2","name":"HER2","href":"/targets/her2/"},"b":{"key":"platform","id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/"},"state":"development","drugs":[{"id":"glsi-100","name":"GLSI-100","route":"/drugs/glsi-100/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"target":[{"key":"target","id":"her2","name":"HER2","href":"/targets/her2/"}]},"evidence":[{"record":"glsi-100","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/glsi-100/"},{"record":"nct05232916","field":"status","kind":"trial","state":"development","label":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects: phase 3, recruiting","href":"/trials/nct05232916/"},{"record":"registry:glsi-100","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/glsi-100/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"her2+ceacam5+tp53","name":"HER2 x CEACAM5 x TP53","href":"/targets/her2/"},"b":{"key":"platform","id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/"},"state":"development","drugs":[{"id":"ose2101","name":"OSE2101","route":"/drugs/ose2101/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"target":[{"key":"target","id":"her2+ceacam5+tp53","name":"HER2 x CEACAM5 x TP53","href":"/targets/her2/"}]},"evidence":[{"record":"ose2101","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ose2101/"},{"record":"nct05751798","field":"status","kind":"trial","state":"development","label":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas: phase 1/2, recruiting","href":"/trials/nct05751798/"},{"record":"nct06472245","field":"status","kind":"trial","state":"development","label":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor: phase 3, recruiting","href":"/trials/nct06472245/"},{"record":"registry:ose2101","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/ose2101/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"kras","name":"KRAS","href":"/targets/kras/"},"b":{"key":"platform","id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/"},"state":"development","drugs":[{"id":"eli-002-7p","name":"ELI-002 7P","route":"/drugs/eli-002-7p/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"target":[{"key":"target","id":"kras","name":"KRAS","href":"/targets/kras/"}]},"evidence":[{"record":"eli-002-7p","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/eli-002-7p/"},{"record":"amplify-7p","field":"result","kind":"trial","state":"stopped","label":"AMPLIFY-7P: phase 1/2, negative","href":"/trials/amplify-7p/","quote":"Primary DFS endpoint not met."},{"record":"registry:eli-002-7p","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/eli-002-7p/#registry"}],"reasons":[{"drugId":"eli-002-7p","drugName":"ELI-002 7P","drugRoute":"/drugs/eli-002-7p/","drugState":"development","record":"amplify-7p","kind":"trial","label":"AMPLIFY-7P: phase 1/2, negative","href":"/trials/amplify-7p/","quote":"Primary DFS endpoint not met."}]},{"a":{"key":"antigen","id":"pdl1+ido1","name":"PD-L1 x IDO1","href":"/targets/pdl1/"},"b":{"key":"platform","id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/"},"state":"development","drugs":[{"id":"io102-io103","name":"IO102-IO103","route":"/drugs/io102-io103/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"target":[{"key":"target","id":"pdl1+ido1","name":"PD-L1 x IDO1","href":"/targets/pdl1/"}]},"evidence":[{"record":"io102-io103","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/io102-io103/"},{"record":"nct05155254","field":"status","kind":"trial","state":"development","label":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18): phase 3, active","href":"/trials/nct05155254/"},{"record":"nct05280314","field":"status","kind":"trial","state":"development","label":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors: phase 2, recruiting","href":"/trials/nct05280314/"},{"record":"registry:io102-io103","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/io102-io103/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"pap","name":"Prostatic acid phosphatase (ACP3, PAP)","href":"/targets/pap/"},"b":{"key":"platform","id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/"},"state":"approved","drugs":[{"id":"sipuleucel-t","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"sipuleucel-t","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sipuleucel-t/"},{"record":"sipuleucel-t","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2010: Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","href":"/drugs/sipuleucel-t/"},{"record":"sipuleucel-t","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2013: Same (withdrawn 2015 for commercial reasons)","href":"/drugs/sipuleucel-t/"},{"record":"sipuleucel-t","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2010","href":"/regulatory/regions/"},{"record":"sipuleucel-t","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/provenge","quote":"Authorised Sep 2013; marketing authorisation withdrawn May 2015 at the holder's request (commercial)"},{"record":"nct06134232","field":"status","kind":"trial","state":"development","label":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T: phase 2, recruiting","href":"/trials/nct06134232/"},{"record":"registry:sipuleucel-t","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/sipuleucel-t/#registry"}],"reasons":[{"drugId":"sipuleucel-t","drugName":"Sipuleucel-T","drugRoute":"/drugs/sipuleucel-t/","drugState":"approved","record":"sipuleucel-t","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/provenge","quote":"Authorised Sep 2013; marketing authorisation withdrawn May 2015 at the holder's request (commercial)"}]},{"a":{"key":"antigen","id":"psma","name":"PSMA","href":"/targets/psma/"},"b":{"key":"platform","id":"dna-plasmid","name":"DNA plasmid","href":"/technologies/shared-antigen-vaccine/"},"state":"development","drugs":[{"id":"ino-5401","name":"INO-5401","route":"/drugs/ino-5401/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"target":[{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/"}]},"evidence":[{"record":"ino-5401","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ino-5401/"},{"record":"nct03491683","field":"status","kind":"trial","state":"development","label":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM): phase 1/2, active","href":"/trials/nct03491683/"},{"record":"registry:ino-5401","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/ino-5401/#registry"}],"reasons":[]},{"a":{"key":"antigen","id":"glycan","name":"Tumour glycan (Globo H)"},"b":{"key":"platform","id":"glycoconjugate","name":"Glycoconjugate","href":"/technologies/shared-antigen-vaccine/"},"state":"development","drugs":[{"id":"adagloxad-simolenin","name":"Adagloxad simolenin","route":"/drugs/adagloxad-simolenin/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"adagloxad-simolenin","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/adagloxad-simolenin/"},{"record":"nct03562637","field":"status","kind":"trial","state":"development","label":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC: phase 3, active","href":"/trials/nct03562637/"},{"record":"registry:adagloxad-simolenin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/adagloxad-simolenin/#registry"}],"reasons":[]}],"components":{"antigen":[{"key":"antigen","id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/","count":6,"drugIds":["autogene-cevumeran","grt-c901","grt-r902","intismeran-autogene","neovax","rindopepimut"],"states":{"approved":0,"development":5,"stopped":1,"unclear":0}},{"key":"antigen","id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/","count":5,"drugIds":["cervavac","hb-200","hpv-bivalent-vaccine","hpv-quadrivalent-vaccine","gardasil-9"],"states":{"approved":4,"development":1,"stopped":0,"unclear":0}},{"key":"antigen","id":"alpha-gal","name":"Alpha-gal (xenoantigen)","count":1,"drugIds":["algenpantucel-l"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"antigen","id":"tumour-lysate","name":"Autologous tumour lysate","count":1,"drugIds":["dcvax-l"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"antigen","id":"brachyury","name":"Brachyury (TBXT)","count":1,"drugIds":["gi-6301"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"antigen","id":"her2","name":"HER2","href":"/targets/her2/","count":1,"drugIds":["glsi-100"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"antigen","id":"her2+ceacam5+tp53","name":"HER2 x CEACAM5 x TP53","href":"/targets/her2/","count":1,"drugIds":["ose2101"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"antigen","id":"kras","name":"KRAS","href":"/targets/kras/","count":1,"drugIds":["eli-002-7p"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"antigen","id":"pdl1+ido1","name":"PD-L1 x IDO1","href":"/targets/pdl1/","count":1,"drugIds":["io102-io103"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"antigen","id":"pap","name":"Prostatic acid phosphatase (ACP3, PAP)","href":"/targets/pap/","count":1,"drugIds":["sipuleucel-t"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"antigen","id":"psma","name":"PSMA","href":"/targets/psma/","count":1,"drugIds":["ino-5401"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"antigen","id":"glycan","name":"Tumour glycan (Globo H)","count":1,"drugIds":["adagloxad-simolenin"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}}],"platform":[{"key":"platform","id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/","count":5,"drugIds":["glsi-100","io102-io103","neovax","ose2101","rindopepimut"],"states":{"approved":0,"development":4,"stopped":1,"unclear":0}},{"key":"platform","id":"vlp","name":"Virus-like particle","href":"/technologies/hpv-vaccine/","count":4,"drugIds":["cervavac","hpv-bivalent-vaccine","hpv-quadrivalent-vaccine","gardasil-9"],"states":{"approved":4,"development":0,"stopped":0,"unclear":0}},{"key":"platform","id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/","count":3,"drugIds":["dcvax-l","eli-002-7p","sipuleucel-t"],"states":{"approved":1,"development":2,"stopped":0,"unclear":0}},{"key":"platform","id":"mrna","name":"mRNA","href":"/technologies/neoantigen-mrna-vaccine/","count":2,"drugIds":["autogene-cevumeran","intismeran-autogene"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"platform","id":"dna-plasmid","name":"DNA plasmid","href":"/technologies/shared-antigen-vaccine/","count":1,"drugIds":["ino-5401"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"platform","id":"glycoconjugate","name":"Glycoconjugate","href":"/technologies/shared-antigen-vaccine/","count":1,"drugIds":["adagloxad-simolenin"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"platform","id":"yeast","name":"Recombinant yeast","href":"/technologies/shared-antigen-vaccine/","count":1,"drugIds":["gi-6301"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"platform","id":"viral-vector","name":"Viral vector","href":"/technologies/shared-antigen-vaccine/","count":1,"drugIds":["hb-200"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"platform","id":"whole-cell","name":"Whole cell","href":"/technologies/shared-antigen-vaccine/","count":1,"drugIds":["algenpantucel-l"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}}],"target":[{"key":"target","id":"egfr","name":"EGFR","href":"/targets/egfr/","count":1,"drugIds":["rindopepimut"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"her2","name":"HER2","href":"/targets/her2/","count":1,"drugIds":["glsi-100"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"her2+ceacam5+tp53","name":"HER2 x CEACAM5 x TP53","href":"/targets/her2/","count":1,"drugIds":["ose2101"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"kras","name":"KRAS","href":"/targets/kras/","count":1,"drugIds":["eli-002-7p"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"pdl1+ido1","name":"PD-L1 x IDO1","href":"/targets/pdl1/","count":1,"drugIds":["io102-io103"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/","count":1,"drugIds":["ino-5401"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}}]},"drugs":[{"id":"adagloxad-simolenin","name":"Adagloxad simolenin","route":"/drugs/adagloxad-simolenin/","status":"phase-3","modality":"Carbohydrate antigen vaccine (Globo H conjugate) with the adjuvant OBI-821","state":"development","confidence":"high","fields":["mechanism","modality"],"components":{"antigen":{"id":"glycan","name":"Tumour glycan (Globo H)","href":null,"confidence":"high","from":["mechanism"],"detail":null},"platform":{"id":"glycoconjugate","name":"Glycoconjugate","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"adagloxad-simolenin","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/adagloxad-simolenin/"},{"record":"nct03562637","field":"status","kind":"trial","state":"development","label":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC: phase 3, active","href":"/trials/nct03562637/"},{"record":"registry:adagloxad-simolenin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/adagloxad-simolenin/#registry"}],"reasons":[]},{"id":"algenpantucel-l","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/","status":"negative","modality":"Allogeneic whole-cell vaccine expressing alpha-gal","state":"stopped","confidence":"high","fields":["mechanism","modality"],"components":{"antigen":{"id":"alpha-gal","name":"Alpha-gal (xenoantigen)","href":null,"confidence":"high","from":["mechanism"],"detail":null},"platform":{"id":"whole-cell","name":"Whole cell","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"algenpantucel-l","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/algenpantucel-l/","quote":"Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit."},{"record":"impress-trial","field":"result","kind":"trial","state":"stopped","label":"IMPRESS (algenpantucel-L): phase 3, negative","href":"/trials/impress-trial/","quote":"No overall survival benefit."},{"record":"registry:algenpantucel-l","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 3 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/algenpantucel-l/#registry"}],"reasons":[{"drugId":"algenpantucel-l","drugName":"Algenpantucel-L","drugRoute":"/drugs/algenpantucel-l/","drugState":"stopped","record":"algenpantucel-l","kind":"drug","label":"Drug record status: negative","href":"/drugs/algenpantucel-l/","quote":"Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit."},{"drugId":"algenpantucel-l","drugName":"Algenpantucel-L","drugRoute":"/drugs/algenpantucel-l/","drugState":"stopped","record":"impress-trial","kind":"trial","label":"IMPRESS (algenpantucel-L): phase 3, negative","href":"/trials/impress-trial/","quote":"No overall survival benefit."}]},{"id":"autogene-cevumeran","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","status":"phase-2","modality":"Personalised mRNA neoantigen vaccine","state":"development","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"mrna","name":"mRNA","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"autogene-cevumeran","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/autogene-cevumeran/"},{"record":"nct05968326","field":"status","kind":"trial","state":"development","label":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC: phase 2, active","href":"/trials/nct05968326/"},{"record":"registry:autogene-cevumeran","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/autogene-cevumeran/#registry"}],"reasons":[]},{"id":"cervavac","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","status":"approved","modality":"Prophylactic vaccine (virus-like particles)","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"vlp","name":"Virus-like particle","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"cervavac","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cervavac/"},{"record":"cervavac","field":"approvals[0]","kind":"approval","state":"approved","label":"IN 2022: Prevention of HPV 6/11/16/18-related cancers and genital warts, ages 9-26","href":"/drugs/cervavac/"},{"record":"cervavac","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved 2022","href":"https://www.seruminstitute.com/product_ind_cervavac.php"},{"record":"registry:cervavac","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/cervavac/#registry"}],"reasons":[]},{"id":"dcvax-l","name":"DCVax-L","route":"/drugs/dcvax-l/","status":"phase-3","modality":"Autologous dendritic cell vaccine (tumour lysate)","state":"development","confidence":"high","fields":["mechanism","modality"],"components":{"antigen":{"id":"tumour-lysate","name":"Autologous tumour lysate","href":null,"confidence":"high","from":["mechanism"],"detail":null},"platform":{"id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dcvax-l","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/dcvax-l/"},{"record":"registry:dcvax-l","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/dcvax-l/#registry"}],"reasons":[]},{"id":"eli-002-7p","name":"ELI-002 7P","route":"/drugs/eli-002-7p/","status":"phase-2","modality":"Off-the-shelf lymph-node-targeted KRAS peptide vaccine","state":"development","confidence":"high","fields":["targets","modality","mechanism"],"components":{"antigen":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"platform":{"id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"eli-002-7p","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/eli-002-7p/"},{"record":"amplify-7p","field":"result","kind":"trial","state":"stopped","label":"AMPLIFY-7P: phase 1/2, negative","href":"/trials/amplify-7p/","quote":"Primary DFS endpoint not met."},{"record":"registry:eli-002-7p","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/eli-002-7p/#registry"}],"reasons":[{"drugId":"eli-002-7p","drugName":"ELI-002 7P","drugRoute":"/drugs/eli-002-7p/","drugState":"development","record":"amplify-7p","kind":"trial","label":"AMPLIFY-7P: phase 1/2, negative","href":"/trials/amplify-7p/","quote":"Primary DFS endpoint not met."}]},{"id":"gi-6301","name":"GI-6301","route":"/drugs/gi-6301/","status":"negative","modality":"Heat-killed recombinant yeast vaccine expressing brachyury","state":"stopped","confidence":"high","fields":["mechanism","modality"],"components":{"antigen":{"id":"brachyury","name":"Brachyury (TBXT)","href":null,"confidence":"high","from":["mechanism"],"detail":null},"platform":{"id":"yeast","name":"Recombinant yeast","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"gi-6301","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/gi-6301/","quote":"GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses."},{"record":"registry:gi-6301","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 17 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/gi-6301/#registry"}],"reasons":[{"drugId":"gi-6301","drugName":"GI-6301","drugRoute":"/drugs/gi-6301/","drugState":"stopped","record":"gi-6301","kind":"drug","label":"Drug record status: negative","href":"/drugs/gi-6301/","quote":"GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses."}]},{"id":"glsi-100","name":"GLSI-100","route":"/drugs/glsi-100/","status":"phase-3","modality":"vaccine","state":"development","confidence":"high","fields":["targets","modality","mechanism"],"components":{"antigen":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":null},"target":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":null},"platform":{"id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"glsi-100","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/glsi-100/"},{"record":"nct05232916","field":"status","kind":"trial","state":"development","label":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects: phase 3, recruiting","href":"/trials/nct05232916/"},{"record":"registry:glsi-100","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/glsi-100/#registry"}],"reasons":[]},{"id":"grt-c901","name":"GRT-C901","route":"/drugs/grt-c901/","status":"phase-3","modality":"vaccine","state":"development","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"grt-c901","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/grt-c901/"},{"record":"nct05141721","field":"status","kind":"trial","state":"development","label":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer: phase 2/3, active","href":"/trials/nct05141721/"},{"record":"registry:grt-c901","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/grt-c901/#registry"}],"reasons":[]},{"id":"grt-r902","name":"GRT-R902","route":"/drugs/grt-r902/","status":"phase-3","modality":"vaccine","state":"development","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"grt-r902","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/grt-r902/"},{"record":"nct05141721","field":"status","kind":"trial","state":"development","label":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer: phase 2/3, active","href":"/trials/nct05141721/"},{"record":"registry:grt-r902","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/grt-r902/#registry"}],"reasons":[]},{"id":"hb-200","name":"HB-200","route":"/drugs/hb-200/","status":"phase-2","modality":"Arenavirus-vector therapeutic vaccine (HPV16 E6/E7)","state":"development","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"viral-vector","name":"Viral vector","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hb-200","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/hb-200/"}],"reasons":[]},{"id":"hpv-bivalent-vaccine","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","status":"approved","modality":"Recombinant virus-like particle vaccine (adjuvanted)","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"vlp","name":"Virus-like particle","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hpv-bivalent-vaccine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/hpv-bivalent-vaccine/"},{"record":"hpv-bivalent-vaccine","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2007: Prevention of premalignant cervical lesions and cervical cancer caused by HPV 16 and 18 from age 9 (Cervarix); anal lesions added later","href":"/drugs/hpv-bivalent-vaccine/"},{"record":"hpv-bivalent-vaccine","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2009: Prevention of cervical cancer and precursor lesions caused by HPV 16 and 18 in females 10 to 25 (discontinued in the US 2016)","href":"/drugs/hpv-bivalent-vaccine/"},{"record":"hpv-bivalent-vaccine","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2007","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix"},{"record":"registry:hpv-bivalent-vaccine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/hpv-bivalent-vaccine/#registry"}],"reasons":[]},{"id":"hpv-quadrivalent-vaccine","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","status":"approved","modality":"Recombinant virus-like particle vaccine","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"vlp","name":"Virus-like particle","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hpv-quadrivalent-vaccine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/hpv-quadrivalent-vaccine/"},{"record":"hpv-quadrivalent-vaccine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: Prevention of cervical, vulvar and vaginal cancers and precancers and genital warts caused by HPV 6, 11, 16 and 18 in females 9 to 26 (males 2009; anal cancer 2010); superseded by Gardasil 9","href":"/drugs/hpv-quadrivalent-vaccine/"},{"record":"hpv-quadrivalent-vaccine","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2006: Prevention of premalignant genital lesions, cervical cancer and genital warts from age 9 (Gardasil); anal lesions and cancer added later","href":"/drugs/hpv-quadrivalent-vaccine/"},{"record":"hpv-quadrivalent-vaccine","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil"},{"record":"nct06465914","field":"status","kind":"trial","state":"development","label":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males: phase 3, active","href":"/trials/nct06465914/"},{"record":"nct04422366","field":"status","kind":"trial","state":"development","label":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females: phase 3, recruiting","href":"/trials/nct04422366/"},{"record":"registry:hpv-quadrivalent-vaccine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/hpv-quadrivalent-vaccine/#registry"}],"reasons":[]},{"id":"ino-5401","name":"INO-5401","route":"/drugs/ino-5401/","status":"phase-2","modality":"vaccine","state":"development","confidence":"high","fields":["targets","modality","mechanism"],"components":{"antigen":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"high","from":["targets"],"detail":null},"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"high","from":["targets"],"detail":null},"platform":{"id":"dna-plasmid","name":"DNA plasmid","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ino-5401","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ino-5401/"},{"record":"nct03491683","field":"status","kind":"trial","state":"development","label":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM): phase 1/2, active","href":"/trials/nct03491683/"},{"record":"registry:ino-5401","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/ino-5401/#registry"}],"reasons":[]},{"id":"intismeran-autogene","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","status":"phase-3","modality":"Personalised mRNA neoantigen vaccine","state":"development","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"mrna","name":"mRNA","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"intismeran-autogene","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/intismeran-autogene/"},{"record":"nct06833073","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011): phase 2, recruiting","href":"/trials/nct06833073/"},{"record":"nct06961006","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012): phase 2, recruiting","href":"/trials/nct06961006/"},{"record":"nct06305767","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005): phase 1/2, active","href":"/trials/nct06305767/"},{"record":"nct07513376","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I : phase 3, recruiting","href":"/trials/nct07513376/"},{"record":"nct06307431","field":"status","kind":"trial","state":"development","label":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).: phase 2, active","href":"/trials/nct06307431/"},{"record":"nct06077760","field":"status","kind":"trial","state":"development","label":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (: phase 3, active","href":"/trials/nct06077760/"},{"record":"nct07221474","field":"status","kind":"trial","state":"development","label":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013): phase 2, recruiting","href":"/trials/nct07221474/"},{"record":"nct06623422","field":"status","kind":"trial","state":"development","label":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009): phase 3, recruiting","href":"/trials/nct06623422/"},{"record":"nct03897881","field":"status","kind":"trial","state":"development","label":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN: phase 2, active","href":"/trials/nct03897881/"},{"record":"registry:intismeran-autogene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/intismeran-autogene/#registry"}],"reasons":[]},{"id":"io102-io103","name":"IO102-IO103","route":"/drugs/io102-io103/","status":"phase-3","modality":"peptide (immunotherapeutic vaccine)","state":"development","confidence":"high","fields":["targets","modality","mechanism"],"components":{"antigen":{"id":"pdl1+ido1","name":"PD-L1 x IDO1","href":"/targets/pdl1/","confidence":"high","from":["targets"],"detail":"dual-target"},"target":{"id":"pdl1+ido1","name":"PD-L1 x IDO1","href":"/targets/pdl1/","confidence":"high","from":["targets"],"detail":"dual-target"},"platform":{"id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"io102-io103","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/io102-io103/"},{"record":"nct05155254","field":"status","kind":"trial","state":"development","label":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18): phase 3, active","href":"/trials/nct05155254/"},{"record":"nct05280314","field":"status","kind":"trial","state":"development","label":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors: phase 2, recruiting","href":"/trials/nct05280314/"},{"record":"registry:io102-io103","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/io102-io103/#registry"}],"reasons":[]},{"id":"neovax","name":"NeoVax","route":"/drugs/neovax/","status":"phase-1","modality":"Personalised neoantigen long-peptide vaccine with poly-ICLC adjuvant","state":"development","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"neovax","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 1","href":"/drugs/neovax/"}],"reasons":[]},{"id":"gardasil-9","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","status":"approved","modality":"Prophylactic vaccine (virus-like particles)","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"antigen":{"id":"hpv","name":"HPV antigens (L1, E6, E7)","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"platform":{"id":"vlp","name":"Virus-like particle","href":"/technologies/hpv-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"gardasil-9","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gardasil-9/"},{"record":"gardasil-9","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Prevention of HPV-related cancers and precancers, ages 9-26; extended to 45 in 2018","href":"/drugs/gardasil-9/"},{"record":"gardasil-9","field":"approvals[1]","kind":"approval","state":"approved","label":"WHO 2022: Single-dose schedule recommended for girls 9-20","href":"/drugs/gardasil-9/"},{"record":"gardasil-9","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"gardasil-9","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil-9"},{"record":"gardasil-9","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Gardasil%209"},{"record":"gardasil-9","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"gardasil-9","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"gardasil-9","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Gardasil%209"},{"record":"registry:gardasil-9","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/gardasil-9/#registry"}],"reasons":[]},{"id":"ose2101","name":"OSE2101","route":"/drugs/ose2101/","status":"phase-3","modality":"vaccine","state":"development","confidence":"high","fields":["targets","modality","mechanism"],"components":{"antigen":{"id":"her2+ceacam5+tp53","name":"HER2 x CEACAM5 x TP53","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":"dual-target"},"target":{"id":"her2+ceacam5+tp53","name":"HER2 x CEACAM5 x TP53","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":"dual-target"},"platform":{"id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ose2101","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ose2101/"},{"record":"nct05751798","field":"status","kind":"trial","state":"development","label":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas: phase 1/2, recruiting","href":"/trials/nct05751798/"},{"record":"nct06472245","field":"status","kind":"trial","state":"development","label":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor: phase 3, recruiting","href":"/trials/nct06472245/"},{"record":"registry:ose2101","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/ose2101/#registry"}],"reasons":[]},{"id":"rindopepimut","name":"Rindopepimut","route":"/drugs/rindopepimut/","status":"negative","modality":"Peptide vaccine (EGFRvIII)","state":"stopped","confidence":"high","fields":["modality","mechanism","targets"],"components":{"antigen":{"id":"personalised-neoantigens","name":"Personalised neoantigens","href":"/technologies/neoantigen-mrna-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null},"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"platform":{"id":"peptide","name":"Peptide","href":"/technologies/shared-antigen-vaccine/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"rindopepimut","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/rindopepimut/","quote":"Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape."},{"record":"act-iv","field":"result","kind":"trial","state":"stopped","label":"ACT IV: phase 3, negative","href":"/trials/act-iv/","quote":"OS 20.1 vs 20.0 months; no benefit."}],"reasons":[{"drugId":"rindopepimut","drugName":"Rindopepimut","drugRoute":"/drugs/rindopepimut/","drugState":"stopped","record":"rindopepimut","kind":"drug","label":"Drug record status: negative","href":"/drugs/rindopepimut/","quote":"Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape."},{"drugId":"rindopepimut","drugName":"Rindopepimut","drugRoute":"/drugs/rindopepimut/","drugState":"stopped","record":"act-iv","kind":"trial","label":"ACT IV: phase 3, negative","href":"/trials/act-iv/","quote":"OS 20.1 vs 20.0 months; no benefit."}]},{"id":"sipuleucel-t","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","status":"approved","modality":"Autologous cellular immunotherapy (antigen-presenting cell vaccine)","state":"approved","confidence":"medium","fields":["mechanism","modality"],"components":{"antigen":{"id":"pap","name":"Prostatic acid phosphatase (ACP3, PAP)","href":"/targets/pap/","confidence":"medium","from":["mechanism"],"detail":null},"platform":{"id":"dendritic-cell","name":"Dendritic or antigen-presenting cell","href":"/technologies/dendritic-cell-vaccines/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sipuleucel-t","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sipuleucel-t/"},{"record":"sipuleucel-t","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2010: Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","href":"/drugs/sipuleucel-t/"},{"record":"sipuleucel-t","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2013: Same (withdrawn 2015 for commercial reasons)","href":"/drugs/sipuleucel-t/"},{"record":"sipuleucel-t","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2010","href":"/regulatory/regions/"},{"record":"sipuleucel-t","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/provenge","quote":"Authorised Sep 2013; marketing authorisation withdrawn May 2015 at the holder's request (commercial)"},{"record":"nct06134232","field":"status","kind":"trial","state":"development","label":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T: phase 2, recruiting","href":"/trials/nct06134232/"},{"record":"registry:sipuleucel-t","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/sipuleucel-t/#registry"}],"reasons":[{"drugId":"sipuleucel-t","drugName":"Sipuleucel-T","drugRoute":"/drugs/sipuleucel-t/","drugState":"approved","record":"sipuleucel-t","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/provenge","quote":"Authorised Sep 2013; marketing authorisation withdrawn May 2015 at the holder's request (commercial)"}]}],"unresolved":[{"id":"bnt113","name":"BNT113","route":"/drugs/bnt113/","format":"vaccine","modality":"mRNA vaccine (per the sponsor's pipeline page; form not stated in the registry record)","missing":["antigen","target"],"why":"No antigen on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"doc1021","name":"DOC1021","route":"/drugs/doc1021/","format":"vaccine","modality":"Cancer vaccine","missing":["antigen","platform","target"],"why":"No antigen on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"evm14","name":"EVM14","route":"/drugs/evm14/","format":"vaccine","modality":"Cancer vaccine","missing":["antigen","platform","target"],"why":"No antigen on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"rv001v","name":"RV001V","route":"/drugs/rv001v/","format":"vaccine","modality":"Cancer vaccine","missing":["antigen","platform","target"],"why":"No antigen on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."}],"stopped":[{"drugId":"algenpantucel-l","drugName":"Algenpantucel-L","drugRoute":"/drugs/algenpantucel-l/","drugState":"stopped","record":"algenpantucel-l","kind":"drug","label":"Drug record status: negative","href":"/drugs/algenpantucel-l/","quote":"Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit."},{"drugId":"algenpantucel-l","drugName":"Algenpantucel-L","drugRoute":"/drugs/algenpantucel-l/","drugState":"stopped","record":"impress-trial","kind":"trial","label":"IMPRESS (algenpantucel-L): phase 3, negative","href":"/trials/impress-trial/","quote":"No overall survival benefit."},{"drugId":"gi-6301","drugName":"GI-6301","drugRoute":"/drugs/gi-6301/","drugState":"stopped","record":"gi-6301","kind":"drug","label":"Drug record status: negative","href":"/drugs/gi-6301/","quote":"GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses."},{"drugId":"rindopepimut","drugName":"Rindopepimut","drugRoute":"/drugs/rindopepimut/","drugState":"stopped","record":"rindopepimut","kind":"drug","label":"Drug record status: negative","href":"/drugs/rindopepimut/","quote":"Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape."},{"drugId":"rindopepimut","drugName":"Rindopepimut","drugRoute":"/drugs/rindopepimut/","drugState":"stopped","record":"act-iv","kind":"trial","label":"ACT IV: phase 3, negative","href":"/trials/act-iv/","quote":"OS 20.1 vs 20.0 months; no benefit."},{"drugId":"eli-002-7p","drugName":"ELI-002 7P","drugRoute":"/drugs/eli-002-7p/","drugState":"development","record":"amplify-7p","kind":"trial","label":"AMPLIFY-7P: phase 1/2, negative","href":"/trials/amplify-7p/","quote":"Primary DFS endpoint not met."},{"drugId":"sipuleucel-t","drugName":"Sipuleucel-T","drugRoute":"/drugs/sipuleucel-t/","drugState":"approved","record":"sipuleucel-t","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/provenge","quote":"Authorised Sep 2013; marketing authorisation withdrawn May 2015 at the holder's request (commercial)"}],"proposed":[],"note":"Every state is derived from the records named in evidence; untried means no medicine in this corpus combines the two parts. Proposed cells are hypotheses from the open pipeline (docs/OPEN-PIPELINE.md), not records of a medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}